Following the loss of patent protection, Novo Nordisk will reduce prices for Ozempic and Wegovy by up to 48%, starting April 1. The company aims to make these essential treatments more affordable for the growing population of diabetes and obesity patients in India.
Novo Nordisk slashes Ozempic, Wegovy prices as generic competition heats up
